All In Biotech

Drug Trial Radar · NCT04161495

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients ≥12 Years of Age With Severe Hemophilia A

Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

Nov 19, 2019

Primary completion

Feb 3, 2022

Study completion Feb 3, 2022

Sponsor

Lead sponsor
Bioverativ, a Sanofi companySanofi (SNY)
Sponsor type
Industry
First posted
Nov 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm. Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. * To evaluate BIVV001 consumption for the prevention and treatment of bleeding episodes. * To evaluate the effect of BIVV001 prophylaxis on joint health outcomes. * To evaluate the effect of BIVV001 prophylaxis on Quality of Life outcomes. * To evaluate the efficacy of BIVV001 for perioperative management. * To evaluate the safety and tolerability of BIVV001 treatment. * To assess the pharmacokinetics (PK) of BIVV001 based on the 1-stage activated partial thromboplastin time (aPTT) and 2-stage chromogenic coagulation factor VIII (FVIII) activity assays.

Conditions

  • Factor VIII Deficiency

Interventions

  • efanesoctocog alfa (BIVV001)Biological

    Pharmaceutical form: solution for injection Route of administration: IV injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Annualized Bleeding Rate (ABR) in Arm A: ProphylaxisTime frame: Baseline to Week 52
  2. Observed Annualized Bleeding Rate in Arm A: ProphylaxisTime frame: Baseline to Week 52

Locations

47 sites in 19 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 920

    Los Angeles, California

  • Investigational Site Number 921

    Los Angeles, California

  • Investigational Site Number 911

    San Diego, California

  • Investigational Site Number 917

    Gainesville, Florida

  • Investigational Site Number 919

    Ann Arbor, Michigan

  • Investigational Site Number 908

    Lansing, Michigan

  • Investigational Site Number 906

    Las Vegas, Nevada

  • Investigational Site Number 902

    Seattle, Washington

  • Investigational Site Number 136

    Buenos Aires, Argentina

  • Investigational Site Number 137

    Buenos Aires, Argentina

  • Investigational Site Number 139

    Mendoza, Argentina

  • Investigational Site Number 121

    Perth, Australia

  • Investigational Site Number 122

    Sydney, Australia

  • Investigational Site Number 161

    Brussels, Belgium

  • Investigational Site Number 181

    Campinas, Brazil

  • Investigational Site Number 171

    Plovdiv, Bulgaria

  • Investigational Site Number 172

    Sofia, Bulgaria

  • Investigational Site Number 202

    Hamilton, Canada

  • Investigational Site Number 205

    Hamilton, Canada

  • Investigational Site Number 281

    Brest, France

  • Investigational Site Number 283

    Lille, France

  • Investigational Site Number 282

    Lyon, France

  • Investigational Site Number 284

    Marseille, France

  • Investigational Site Number 304

    Berlin, Germany

  • Investigational Site Number 302

    Bonn, Germany

  • Investigational Site Number 303

    Frankfurt, Germany

  • Investigational Site Number 321

    Athens, Greece

  • Investigational Site Number 312

    Budapest, Hungary

  • Investigational Site Number 314

    Debrecen, Hungary

  • Investigational Site Number 402

    Milan, Italy

  • Investigational Site Number 401

    Vicenza, Italy

  • Investigational Site Number 426

    Kawasaki, Japan

  • Investigational Site Number 423

    Kitakyushu, Japan

  • Investigational Site Number 425

    Nagoya, Japan

  • Investigational Site Number 422

    Nara, Japan

  • Investigational Site Number 421

    Tokyo, Japan

  • Investigational Site Number 424

    Tokyo, Japan

  • Investigational Site Number 435

    Durango, Mexico

  • Investigational Site Number 641

    Utrecht, Netherlands

  • Investigational Site Number 603

    Daegu, South Korea

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.